Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT02675452 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02675452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02675452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
June 13, 2016
Completion date
May 27, 2024
Enrollment
141 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute myeloid leukemia, relapsed or refractory multiple myeloma